Rajesh P Ringe, Philippe Colin, Gabriel Ozorowski, Joel D Allen, Anila Yasmeen, Gemma E Seabright, Jeong Hyun Lee, Aleksandar Antanasijevic, Kimmo Rantalainen, Thomas Ketas, John P Moore, Andrew B Ward, Max Crispin, P J Klasse
Neutralizing antibodies (NAbs) to multiple epitopes on the HIV-1-envelope glycoprotein (Env) have been isolated from infected persons. The potency of NAbs is measured more often than the size of the persistent fraction of infectivity at maximum neutralization, which may also influence preventive efficacy of active or passive immunization and the therapeutic outcome of the latter. Many NAbs neutralize HIV-1 CZA97.012, a clone of a Clade-C isolate, to ~100%. But here NAb PGT151, directed to a fusion-peptide epitope, left a persistent fraction of 15%...
October 2023: PLoS Pathogens